-
Hong Kong stocks CRO concept sector changes, many stocks closed up more than 7%
Time of Update: 2022-08-15
As of the close, Zhaoyan New Drug rose by the daily limit, with an increase of 10%, WuXi Biologics rose by more than 8%, GenScript Biotechnology, Kay Laying rose more than 7%, Tiger Pharmaceuticals, WuXi PharmaTech and others followed suit [Pharmaceutical Network Pharmaceutical Stock Market] On July 4, the CRO concept sector of Hong Kong stocks changed, and many stocks rose significantly.
-
General Administration of Customs: Strictly prevent the introduction of acute severe hepatitis in children of unknown cause
Time of Update: 2022-08-15
(Headquarters CCTV reporter Sun Shuwen and Kong Lingwen) In response to reports of unexplained acute severe hepatitis cases in children in many countries around the world, the General Administration of Customs has recently made arrangements for health and quarantine related work at customs ports across the country to prevent the spread of the epidemic into China .
-
The speed of generic drugs "going overseas" has intensified, and the news of foreign approval of products continues
Time of Update: 2022-08-15
After this approval, according to the US CGT (competitive generic therapy) Act, Hengrui Medicine Iodixanol injection will obtain a 180-day market exclusivity period, and is expected to become a product of Hengrui Medicine with overseas sales of over US$100 million At the end of May this year, Hengrui Medicine's iodixanol was approved in the ANDA (generic drug listing) application in the United States.
-
The pharmaceutical industry is favored by institutions, and this pharmaceutical company has been investigated by hundreds of institutions
Time of Update: 2022-08-15
The types of institutions are QFII, insurance companies, others, fund companies, overseas institutions, securities companies, Sunshine Private Equity For example, Huadong Medicine released a record form of investor relations activities on July 11, and the company received 134 institutional surveys on July 8, 2022.
-
2 Successful IPO registration of pharmaceutical companies: high-end preparations and high-end medical equipment enter the fast lane
Time of Update: 2022-08-15
34 million shares in an initial public offering and raise 600 million yuan, which will be mainly used for the preparation production complex building and related supporting facilities projects, high-end generic drugs and improved new drug research and development projects and supplementary Liquidity According to the prospectus of Xuantai Pharmaceuticals, Xuantai Pharmaceuticals plans to issue 45.
-
A number of blockbuster new drugs have been approved for clinical use, and domestic anti-tumor drugs are about to usher in the harvest period
Time of Update: 2022-08-15
-AS269 conjugate (ARX305) "Drug Clinical Trial Approval Notice", agreeing to carry out clinical trials of this product as a single drug in patients with advanced tumors For example, on July 12, Zhejiang Pharmaceutical issued an announcement stating that its subsidiary Zhejiang Xinma Bio-Pharmaceutical Co.
-
Only 6 imported drugs are to be selected for the seventh batch of centralized procurement. Do multinational pharmaceutical companies choose to "lie down"?
Time of Update: 2022-08-15
For example, Huizhi's lipid-lowering drug Lipitor (atorvastatin calcium tablets), which was transferred to the out-of-hospital market after the first batch of national centralized procurement failed to win the bid, the company stated in its 2021 financial report that the growth of new channels will partly This offset the decline in sales in hospitals due to volume purchases .
-
The market size of liver disease drugs is expected to reach 100 billion, and domestic pharmaceutical companies are expected to become the winners
Time of Update: 2022-08-15
[Pharmaceutical Network Market Analysis] July 28 is the twelfth World Hepatitis Day . Hepatitis is an inflammation of the liver caused by viruses, bacteria, parasites, chemical poisons, alcohol, auto
-
Changes in the pharmaceutical sector, Xinhua Pharmaceutical, Yuheng Pharmaceutical and other stocks closed at the daily limit
Time of Update: 2022-08-15
Analysis believes that the stock's daily limit is related to these two drugs The company's main business is the production and sales of Chinese and Western medicine injections.
-
The "involution" of generic drugs has intensified, and innovative drugs will bring a blue ocean of development to pharmaceutical companies
Time of Update: 2022-08-15
. On July 15, Sihuan Pharmaceutical announced that the company intends to propose the sale of some or all of its generic drugs and other non-core traditional medicine businesses that have not met the company's performance expectations or are not in line with the company's long-term strategic goals due to changes in the pharmaceutical industry.
-
Behind the accelerated withdrawal of Chinese patent medicines from medical insurance, what should Chinese medicine companies do?
Time of Update: 2022-08-15
In addition, compared with proprietary Chinese medicines, the industry generally believes that Chinese herbal decoction pieces and formula granules are less pressured by medical insurance to control costs and have growth potential .
-
This pharmaceutical stock hit a new high in 6 months, and its net profit increased by more than 15% in the first half of the year
Time of Update: 2022-08-15
91 million yuan, a year-on-year increase of 50% Among them, in the first half of 2022 alone, the company's research and development expenses reached 83.
-
The global transdermal drug delivery market is expected to reach 200 billion yuan, and my country still has considerable room for development
Time of Update: 2022-08-15
, a subsidiary of MicroPort Group, to jointly invest in the establishment of a joint venture company for pharmaceutical equipment and give full play to their respective With the advantages and resources in the fields of transdermal drug delivery systems, new drug development and pharmaceutical research, we will realize complementary advantages and carry out in-depth cooperation in the field of polypeptide microneedle transdermal drug delivery .
-
The traditional Chinese medicine ETF, which closely tracks the CSI Traditional Chinese Medicine Index, has officially opened for listing and trading!
Time of Update: 2022-08-15
. In addition, in recent years, the relevant favorable policies from the state to the local government have also supported the development of traditional Chinese medicine, and the previous overall planning outline has been converted into more specific development rules, including medical insurance payment, drug review and approval, talent training, etc.
-
Pharmaceutical growth is still very rigid, it is recommended to pay attention to the three main lines and these individual stocks
Time of Update: 2022-08-15
;Focusing on the development strategy of "reinforcing the foundation, extending the breakthrough, and innovating and exploring", consolidate the three core products and break through the functional health care category; provide solutions according to the needs of the market and customers, enhance the ability and innovation vitality of digital organizations, and continuously improve profitability ability and operating efficiency, and achieve healthy and healthy development of the company .
-
The market prospect of cell therapy equipment is considerable, and domestic enterprises are constantly making efforts in the direction of automation
Time of Update: 2022-08-15
[Pharmaceutical Network Market Analysis] Cell therapy represented by stem cells and immune cells is attracting widespread attention . In 2021, two domestic CAR-T cell therapy drugs, Akilenxe Injectio
-
With the advancement of new medical reforms such as centralized procurement, such pharmaceutical companies may gradually withdraw from the market
Time of Update: 2022-08-15
The industry believes that the realization of a vertically integrated industry chain of "API + preparation" will help Chinese generic drug companies to reduce costs and improve profit So, how should pharmaceutical companies transform?
-
The latest news on the policy of online sales of prescription drugs!
Time of Update: 2022-08-15
In 2018, the "Measures for the Supervision and Administration of Online Drug Sales (Draft for Comment)" stated that if the online drug sellers are drug retail chain enterprises, they are not allowed to sell prescription drugs and drugs with special national management requirements through the Internet; sell to individual consumers.
-
Chain pharmacies are about to enter the "10,000-store era", and a large number of single drugstores are facing reshuffle
Time of Update: 2022-08-15
Industry analysts believe that in the second half of the year, the major chain pharmacies will speed up their staking, and the "10,000-store era" is just around the corner The size of the store is a demonstration of the core competitiveness of pharmaceutical retail enterprises.
-
The report on the procurement of magnetic therapy equipment in the first quarter of 2022 is released, and this province is the most active
Time of Update: 2022-08-12
Data source: JOINCHAIN ® Zhongcheng Digital Science Observation from the model, in the first quarter of 2022, the magnetic therapy equipment of Osaifu model MS 080 ranked first, of which the total bid amount and quantity were 2.
